High-protein, low-calorie oral nutritional supplements (ONS) are projected to capture 43.3% of product type demand in 2026, as the global obesity-related malnutrition nutrition market expands from USD 242.2 million in 2026 to USD 634.0 million by 2036, according to the latest research report published by Future Market Insights.

The obesity-related malnutrition nutrition market is emerging as a critical clinical category alongside the rapid global adoption of GLP-1 receptor agonists, bariatric surgical interventions, and intensive clinical weight-management therapies. As potent appetite suppression significantly reduces voluntary caloric intake, healthcare professionals are confronting a major secondary risk: treatment-induced malnutrition, marked by disproportionate lean muscle loss, micronutrient deficiencies, and severe gastrointestinal intolerance.

Clinical societies and national health services are establishing structured care guidelines to mitigate these risks: in May 2025, The Obesity Society and collaborating medical organizations identified acute muscle and bone density loss, micronutrient shortfalls, and GI complications as key clinical priorities in anti-obesity medication regimens. Concurrently, public health commissioning such as NHS England's phased tirzepatide rollout requiring structured clinical and behavioral "wraparound care" is transforming companion medical nutrition from an ad-hoc consumer purchase into a clinician-monitored therapy.

Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends:
https://www.futuremarketinsights.com/reports/sample/rep-gb-35139

Future Market Insights estimates that the global obesity-related malnutrition nutrition market will expand at a double-digit 10.1% CAGR between 2026 and 2036, adding more than USD 391 million in incremental value over the ten-year forecast window.

The primary commercial bottleneck remains out-of-pocket funding and product tolerability: while drug insurance coverage expands (including initiatives like the U.S. CMS BALANCE model), companion medical nutrition is frequently excluded from pharmaceutical benefits, leaving repeat purchasing exposed to household budgets. Furthermore, GLP-1-induced nausea, early satiety, and delayed gastric emptying require low-volume, nutrient-dense formats that patients can consume without digestive distress.

How Are Different Companies Approaching the Obesity-Related Malnutrition Opportunity?
The competitive landscape divides between clinical medical-nutrition conglomerates, specialized weight-management and direct-to-consumer platforms, and targeted bariatric/micronutrient brands. Global clinical leaders such as Abbott (launching Protality to target muscle preservation during weight loss), Nestlé Health Science, Danone Nutricia (expanding specialized plant-based medical nutrition like Fortimel Plantbased Protein and integrating Kate Farms), and Fresenius Kabi (deploying Fresubin plant-based formats) leverage established institutional channels, clinical trials, and multi-channel retail distribution.

Concurrently, structured weight-management platforms like Medifast (introducing OPTAVIA ASCEND and the Trilivy metabolic health system with dedicated coaching) connect companion nutrition packs directly to active pharmacotherapy users. Meanwhile, specialized clinical nutrition and bariatric brands like Medtrition (launching low-volume, 20g protein ProSource Cups), Celebrate Vitamins, and Victus focus on highly concentrated, chewable, or low-volume micro-servings tailored for altered gastrointestinal anatomies.

This market structure highlights distinct operating strategies: multinational medical-nutrition brands prioritize hospital and clinical-trial validation, weight-management platforms emphasize coach-led consumer compliance and DTC subscription models, and bariatric specialists focus on specific bioavailable nutrient forms that minimize stomach volume impact.

The shared commercial objective is volume-efficient nutrient delivery: a companion nutrition product achieves sustained adherence only when it provides complete protein and essential micronutrients in a serving small enough to tolerate during periods of severe appetite reduction.

Why Do High-Protein Low-Calorie ONS Formulations Lead Product Demand?
High-protein low-calorie ONS is projected to lead the product type category with a 43.3% market share in 2026, driven by clinical protocols requiring skeletal muscle preservation without disrupting the patient's therapeutic energy deficit.

When patients experience rapid pharmacotherapy-induced or post-surgical weight loss, a substantial portion of mass lost can be lean body tissue. Concentrated, low-calorie ONS formulas enable clinical dietitians to prescribe 20 to 30 grams of high-biological-value protein in compact, easily digestible 100-to-150-calorie servings, ensuring nitrogen balance without adding unwanted sugars or excess fats.

Standalone Market Stat: The global obesity-related malnutrition nutrition market is forecast to add more than USD 391.8 million in value between 2026 and 2036.

Analyst Perspective
“Protein density alone does not secure repeat use because reduced appetite puts serving volume and tolerance under equal pressure. The strongest offers tie a defined nutrition target to clinician guidance and a replenishment route patients can sustain.” — Nandini Roy Choudhury, Principal Consultant, Future Market Insights

Market Snapshot
• Market Size (2026): USD 242.2 million
• Forecast Value (2036): USD 634.0 million
• Forecast CAGR: 10.1% from 2026 to 2036
• Leading Product Type: High-protein low-calorie ONS, capturing a projected 43.3% share in 2026
• Leading Context: GLP-1 / pharmacotherapy users, accounting for 48.9% of demand in 2026
• Leading Product Form: Ready-to-drink (RTD), holding 49.9% of market volume in 2026
• Leading End User: Home / self-care, representing 54.7% in 2026
• Leading Sales Channel: Online / DTC, accounting for 40.2% in 2026
• Fastest-Growing Country: South Korea at a 10.4% CAGR

What Is Driving Demand Across the Market?
GLP-1 and pharmacotherapy users represent the largest context segment at 48.9% share in 2026, as millions of patients initiating weekly injections face immediate reductions in meal frequency and volume, making targeted supplementation necessary to avoid nutrient shortfalls.

Ready-to-drink (RTD) product forms lead format demand at 49.9% in 2026, eliminating powder-mixing friction and delivering fixed, measurable nutrient doses to patients managing nausea or low energy.

Home / self-care anchors end-user demand at 54.7% share in 2026, reflecting that the vast majority of nutritional management occurs in domestic environments between outpatient physician visits.

Geographically, South Korea leads country-level expansion at a 10.4% CAGR through 2036, propelled by a fast-growing self-pay obesity care market, rapid digital healthcare adoption, and mobile commerce refill platforms. The United Kingdom follows at a 9.8% CAGR, underpinned by formalized NHS primary-care prescribing frameworks, while the United States (9.5%), Germany (9.2%), and Japan (8.3%) represent established clinical markets balancing clinical nutrition recommendations with self-care retail replenishment.

Exclusive Discounts on Full Report: https://www.futuremarketinsights.com/reports/obesity-related-malnutrition-nutrition-market

About the Report
The Obesity-Related Malnutrition Nutrition Market report provides comprehensive commercial analysis of targeted protein, micronutrient, and oral medical-nutrition products formulated to treat nutritional deficits and lean-mass loss during obesity management.

The research segments the market by product type (high-protein low-calorie ONS, micronutrient repletion blends, GLP-1 companion nutrition, protein-sparing meal products, others), context (GLP-1 / pharmacotherapy users, post-bariatric surgery, sarcopenic obesity, others), product form (RTD, powders, puddings & semi-solids, others), end user (home / self-care, obesity clinics & hospitals, others), sales channel (online / DTC, retail pharmacy, supermarkets & hypermarkets, specialty & health stores, others), and 20+ national markets.

The analysis synthesizes primary interviews with bariatric dietitians, obesity medicine physicians, and specialized nutrition brand executives, supported by desk research across governmental clinical datasets (U.S. CDC/NCHS, NHS England, German Robert Koch Institute, Japan MHLW, South Korea KDCA), medical association guidelines (The Obesity Society, Obesity Medicine Association), and corporate financial filings.
Explore More Related Studies Published by FMI Research
Nutritional Yeast Market: https://www.futuremarketinsights.com/reports/nutritional-yeast-market
Nutritional Bars Market: https://www.futuremarketinsights.com/reports/nutritional-bars-market
Nutritional Yeast Seasoning Market: https://www.futuremarketinsights.com/reports/nutritional-yeast-seasoning-market
Anti-Obesity Therapeutics Market: https://www.futuremarketinsights.com/reports/anti-obesity-therapeutics-market

About Future Market Insights (FMI)
Future Market Insights (FMI) delivers actionable, decision-focused market intelligence that goes beyond traditional research reports.

The company provides:
• In-depth pricing and cost benchmarking analysis
• Demand forecasting based on real industry inputs
• Procurement and buyer behavior insights
• Supply chain and trade flow intelligence
• Technology and application trend analysis across industries

FMI follows a robust bottom-up research methodology, combining insights from industry experts, procurement leaders, manufacturers, and technical professionals to ensure accurate and practical market intelligence.

For Press & Corporate Inquiries
Rahul Singh AVP - Marketing and Growth Strategy
Future Market Insights,
Inc. +91 8600020075
For Sales - [email protected]
For Media - [email protected]
For Web - https://www.futuremarketinsights.com/